Abstract:Background: Randomized studies have shown that the addition of weekly cetuximab to FOLFOX or FOLFIRI improves clinical outcome in the first-line treatment of patients with KRAS wild-type metastatic colorectal cancer (mCRC). This Asia-Pacific multicenter non-randomized phase II study investigated the efficacy and safety of both FOLFOX and FOLFIRI in combination with every 2 weeks cetuximab as first-line therapy in patients with KRAS wild-type mCRC. Methods: Eligible patients received every 2 weeks cetuximab (day 1, 500 mg/m2 every 14 days) with, based on investigator's choice, either FOLFOX (oxaliplatin 100 mg/m2, folinic acid [FA] 200 mg/m2 L-form or 400 mg/m2 racemic, then 5-fluorouracil [5-FU], as a 400 mg/m2 iv bolus and a 2400 mg/m2 infusion over 46 h) or FOLFIRI (irinotecan 180 mg/m2, FA 200 mg/m2 L-form, or 400 mg/m2 racemic, then 5-FU, as a 400 mg/m2 iv bolus and a 2400 mg/m2 infusion over 46 h). Study treatment was continued until disease progression, the occurrence of unacceptable toxicity or consent withdrawal. The primary endpoint was tumor response; assessed radiologically (RECIST 1.0) every 8 weeks. Results: Data cut-off was 86 weeks after the date of the last patient included. The intention to treat (ITT)/safety population comprised 289 patients; 65.1% received FOLFOX plus cetuximab and 34.9% FOLFIRI plus cetuximab. Baseline characteristics were generally well balanced between treatment groups. However, leukocyte count >10000/mm3 was more frequent (16.5% vs 7.9%) and prior adjuvant treatment less frequent (21.3% vs 46.5%) in patients receiving FOLFOX plus cetuximab. A best overall response (complete + partial) rate of 58.8% and a median progression-free survival (mPFS) time of 11.1 months were observed in the combined ITT population (Table). 70.9% of patients showed ≥20% reduction in tumor diameter at 8 weeks from baseline. A post-hoc analysis showed a mPFS time of 12.7 months for this group. The overall R0 resection rate in the ITT population was 10.0%. Survival data are not yet mature. Cetuximab dose intensity was >80% in 77.7% of patients in the FOLFOX plus cetuximab group and 74.3% of patients in the FOLFIRI plus cetuximab group. The most frequent grade 3/4 adverse events (reported for >10% of patients in either arm) were neutropenia, diarrhea, hypokalemia, neuropathy (FOLFOX plus cetuximab group only) and skin reactions. Conclusion: In this study population from the Asia-Pacific region, first-line treatment with chemotherapy plus cetuximab was active and well-tolerated. Efficacy and safety profiles of every 2 weeks cetuximab combined with FOLFOX or FOLFIRI were similar to those reported for either chemotherapy plus weekly cetuximab in pivotal studies.Table Open table in a new tab

Phase II Study of S-1 Plus Leucovorin (1 Week Treatment Regimen Followed by 1 Week Rest Period) in Patients with Untreated Metastatic Colorectal Cancer in Japan and China: Comparing Results of Each Country and Updating Overall Survival

Cetuximab Plus Mfolfox-6 As First-Line Therapy for Unresectable Liver Metastasis from Colorectal Cancer: an Open, Non-Randomized, Multicenter Phase Ii Clinical Trial

Cetuximab Plus Mfolfox-6 As First-Line Therapy for Patients with Kras Wild-Type Unresectable Colorectal Liver-Limited Metastases: an Open, Non-Randomized, Multicenter Phase Ii Clinical Trial (clime Study)

China Special Issue on Gastrointestinal Tumors‐cetuximab Retreatment Plus Camrelizumab and Liposomal Irinotecan in Patients with RAS Wild‐type Metastatic Colorectal Cancer: Cohort B of the Phase II CRACK Study

Phase II Study of S-1 Plus Leucovorin (a New 1-Week Treatment Regimen Followed by a 1-Week Rest Period) in Patients with Untreated Metastatic Colorectal Cancer in Japan and China.

Phase II Study of S-1 Plus Leucovorin (New 1 Week Treatment Regimen Followed by 1 Week Rest Period) in Patients with Untreated Metastatic Colorectal Cancer in Japan and China

Phase II study of oxaliplatin combined with S-1 and leucovorin (SOL) for Chinese patients with metastatic colorectal cancer

Phase II Study of S‐1 Plus Leucovorin in Patients with Metastatic Colorectal Cancer: Regimen of 1 Week On, 1 Week Off

A Phase II trial of oxaliplatin, folinic acid, and 5-fluorouracil (FOLFOX4) as first-line chemotherapy in advanced colorectal cancer: a China single-center experience.

A Phase III Study of Comparing FOLFOX+/-bevacizumab with FOLFOX+/-bevacizumab+ High-Dose Intravenous Vitamin C As First-Line Therapy in Patients with Advanced Colorectal Cancer.

Randomized Controlled Trial of Cetuximab Plus Chemotherapy for Patients with KRAS Wild-Type Unresectable Colorectal Liver-Limited Metastases.

Efficacy and Safety of KH903 Plus FOLFIRI As A Second-line Treatment in Unresectable Recurrent or Metastatic Colorectal Cancer: A Randomized Phase 2 Study

First-Line Cetuximab with Folfox or Folfiri Every 2 Weeks in Kras Wild-Type Metastatic Colorectal Cancer: Phase II Apec Study

Efficacy and Safety of Every-2-weeks Cetuximab Combined with FOLFOX or FOLFIRI As First-Line Therapy in Patients with KRAS Wild-Type Metastatic Colorectal Cancer (mcrc): an Asia-Pacific Nonrandomized Phase II Study (APEC).

Phase II Study of S-1 and Irinotecan Plus Bevacizumab as Second-line Treatment for Patients With Metastatic Colorectal Cancer Resistant to the Fluoropyrimidine-oxaliplatin-cetuximab Regimen

Multicenter phase II study of combination therapy with cetuximab and S-1 in patients with KRAS exon 2 wild-type unresectable colorectal cancer previously treated with irinotecan, oxaliplatin, and fluoropyrimidines (KSCC 0901 study)

Phase II Trial of S-1 and Oxaliplatin Plus Cetuximab for Colorectal Cancer Patients with Initially Unresectable or Not Optimally Resectable Liver Metastases (KSCC1002)

A phase 2 trial of sintilimab (IBI 308) in combination with CAPEOX and bevacizumab (BBCAPX) as first-line treatment in patients with RAS-mutant, microsatellite stable, unresectable metastatic colorectal cancer.

Sintilimab Plus Bevacizumab, Oxaliplatin and Capecitabine As First-Line Therapy in RAS-mutant, Microsatellite Stable, Unresectable Metastatic Colorectal Cancer: an Open-Label, Single-Arm, Phase II Trial

Final Analysis of the Phase 2 Apec Study: Overall Survival (os) Data and Biomarker Subanalyses for First-Line Folfox or Folfiri with Cetuximab (cet) Once Every 2 Weeks in Patients (pts) with Kras or Ras (kras and Nras, Exons 2-4) Wild-Type (wt) Metastatic Colorectal Cancer (Mcrc).

A Prospective Phase II Study of Raltitrexed Combined with S‐1 As Salvage Treatment for Patients with Refractory Metastatic Colorectal Cancer